1559 related articles for article (PubMed ID: 27082776)
1. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
2. Specific antidotes in development for reversal of novel anticoagulants: a review.
Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
[TBL] [Abstract][Full Text] [Related]
3. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
4. Reversal of direct oral anticoagulants: a practical approach.
Shih AW; Crowther MA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
[TBL] [Abstract][Full Text] [Related]
5. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Boda Z
Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
[TBL] [Abstract][Full Text] [Related]
7. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
8. Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Reddy ST; Cossey TC; Savitz SI; Grotta JC
Curr Neurol Neurosci Rep; 2017 Sep; 17(9):67. PubMed ID: 28735353
[TBL] [Abstract][Full Text] [Related]
9. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Enríquez A; Baranchuk A; Corbalán R
Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
[TBL] [Abstract][Full Text] [Related]
10. [Direct oral anticoagulant associated bleeding].
Godier A; Martin AC; Rosencher N; Susen S
J Mal Vasc; 2016 Jul; 41(4):272-8. PubMed ID: 27297642
[TBL] [Abstract][Full Text] [Related]
11. Reversal agents for non-vitamin K antagonist oral anticoagulants.
Levy JH; Douketis J; Weitz JI
Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Reversal of Direct Oral Anticoagulants.
Farina N; Miller JT
Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
[TBL] [Abstract][Full Text] [Related]
15. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ; Ziebell CM
Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
17. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
18. Reversal strategies in patients treated with direct oral anticoagulants.
Gressenberger P
Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
[No Abstract] [Full Text] [Related]
19. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.
Hu TY; Vaidya VR; Asirvatham SJ
Vasc Health Risk Manag; 2016; 12():35-44. PubMed ID: 26937198
[TBL] [Abstract][Full Text] [Related]
20. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
